![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Janssen’s HIV Regimen Earns Funding From NHS England
Janssen’s HIV Regimen Earns Funding From NHS England
![Janssen logo](https://www.fdanews.com/ext/resources/test/Drug-Images2/Janssen.gif?t=1607031430&width=430)
October 9, 2018
NHS England agreed to offer Janssen’s combination HIV-1 treatment Symtuza through the national health service.
Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), which is taken without other antiretroviral medicines, is for patients who have not received anti-HIV-1 medicines in the past and who require a darunavir-based single tablet regimen.
The once-daily regimen is for adults and adolescents aged 12 years and older with a body weight of at least 40 kilograms (88.2 pounds).
The FDA approved Symtuza in July.
Upcoming Events
-
21Oct